ProtAb Ltd. Awarded Chinese Patent for Lead Humanized Antibody, Prozumab
Jerusalem, Israel – December 12, 2014 - ProtAb Ltd. (ProtAb), a Hadasit Bio-Holdings (HBL, TASE: HDST / OTCQB: HDASY) portfolio company, today announced that it has been awarded a key patent by State Intellectual Property Office of the People’s Republic of China.The patent, titled “HUMANIZED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6 METHODS AND USES THEREOF” (application no. 201080050177.2), covers humanized antibodies including lead product candidate Prozumab, as well as the use of Prozumab and other humanized antibodies to treat arthritis and inflammatory bowel disease.
The award of this patent, which protects the Company’s technology through September 2030, follows the November 2013 approval by the U.S. Patent & Trademark Office. The Company has patent applications under review in a number of other countries.
“We are pleased that China’s State Intellectual Property Office has recognized the uniqueness and innovation behind Prozumab with this patent award. With compelling proof of concept and pre-clinical data and a distinct mechanism of action, we believe that Prozumab represents a novel therapeutic candidate with significant potential to treat IBD and other autoimmune and inflammatory diseases,” said ProtAb CEO Shira Yair. “Additionally, we continue to explore Prozumab’s potential in other indications, specifically those that represent orphan disease indications, on the pathway towards initiation of clinical development with Prozumab.”
ProtAb is focused on the development of novel therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune inflammatory diseases. ProtAb has successfully completed the humanization of Prozumab and established preclinical proof-of-concept (POC) for Prozumab, demonstrating a significant effect in various experimental autoimmune disease models including those for inflammatory bowel diseases (IBD) and rheumatoid arthritis. The company has developed extensive manufacturing procedures, which have been up-scaled for GMP production, completed GLP toxicology experiments in rodents and undergone a pre-IND meeting with the FDA.
ProtAb is currently carrying out pre-clinical POC experiments in various additional animal models of autoimmune inflammatory diseases, specifically focused on potential orphan drug indications, to identify the lead indication for clinical development. In addition, through an agreement with the US National Institutes of Health, the Company is executing certain feasibility studies in Behcet’s Disease, a multi-systemic, immune-mediated orphan disease.